Abstract
Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.
Publication types
-
Clinical Trial, Phase II
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Boronic Acids / administration & dosage
-
Boronic Acids / adverse effects
-
Boronic Acids / therapeutic use*
-
Bortezomib
-
Disease-Free Survival
-
Female
-
Humans
-
Lymphoma, Follicular / drug therapy*
-
Male
-
Middle Aged
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / therapeutic use*
-
Pyrazines / administration & dosage
-
Pyrazines / adverse effects
-
Pyrazines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Protease Inhibitors
-
Pyrazines
-
Bortezomib